Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia.

ABSTRACT:

Background

Although children with acute lymphoblastic leukemia (ALL) mount immune responses after vaccination with the trivalent influenza vaccine (TIV), these responses are lower compared to controls. Recently, a high dose (HD) TIV was found to increase the level of antibody response in elderly patients compared to the standard dose (SD) TIV. We hypothesized that the HD TIV would be well-tolerated and more immunogenic compared to the SD TIV in pediatric subjects with ALL.

Procedure

This was a randomized, double-blind, phase I safety trial comparing the HD to the SD TIV in children with ALL. Our secondary objective was immunogenicity. Subjects were randomized 2:1 to receive either the HD (60 µg) or the SD (15 µg) TIV. Local and systemic reactions were solicited, hemagglutini

SUBMITTER: McManus M 

PROVIDER: S-EPMC4310469 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature